Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) rose 3% on Monday . The company traded as high as $38.62 and last traded at $37.35, with a volume of 930,110 shares traded. The stock had previously closed at $36.25.

PCRX has been the subject of a number of recent research reports. BMO Capital Markets reiterated a “sell” rating and set a $36.00 price target on shares of Pacira Pharmaceuticals in a research note on Tuesday, July 19th. Wedbush restated an “outperform” rating and issued a $113.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, May 4th. Mizuho restated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, June 22nd. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research note on Tuesday, July 26th. Finally, Canaccord Genuity restated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, April 20th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Pacira Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $73.82.

The stock’s market capitalization is $1.42 billion. The company has a 50 day moving average price of $37.28 and a 200 day moving average price of $49.87.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Monday, May 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.08. The firm had revenue of $65.50 million for the quarter, compared to analyst estimates of $67.11 million. During the same period last year, the firm posted $0.27 EPS. The business’s revenue was up 12.3% compared to the same quarter last year. Analysts predict that Pacira Pharmaceuticals Inc. will post $0.29 EPS for the current year.

In related news, VP Lauren Bullaro Riker sold 938 shares of the company’s stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $47.66, for a total value of $44,705.08. Following the completion of the sale, the vice president now owns 5,945 shares of the company’s stock, valued at $283,338.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kristen Marie Williams sold 600 shares of the company’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $47.20, for a total transaction of $28,320.00. Following the completion of the sale, the chief accounting officer now directly owns 6,900 shares of the company’s stock, valued at approximately $325,680. The disclosure for this sale can be found here.

A number of large investors recently bought and sold shares of PCRX. Mutual of America Capital Management LLC increased its stake in Pacira Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 24,198 shares of the company’s stock valued at $1,858,000 after buying an additional 142 shares during the last quarter. Stephens Inc. AR increased its stake in Pacira Pharmaceuticals by 3.9% in the fourth quarter. Stephens Inc. AR now owns 21,557 shares of the company’s stock valued at $1,655,000 after buying an additional 806 shares during the last quarter. Rhumbline Advisers increased its stake in Pacira Pharmaceuticals by 8.0% in the fourth quarter. Rhumbline Advisers now owns 42,471 shares of the company’s stock valued at $3,261,000 after buying an additional 3,160 shares during the last quarter. New York State Common Retirement Fund increased its stake in Pacira Pharmaceuticals by 38.1% in the fourth quarter. New York State Common Retirement Fund now owns 57,483 shares of the company’s stock valued at $4,414,000 after buying an additional 15,867 shares during the last quarter. Finally, Morgan Stanley increased its stake in Pacira Pharmaceuticals by 28.7% in the fourth quarter. Morgan Stanley now owns 120,614 shares of the company’s stock valued at $9,261,000 after buying an additional 26,865 shares during the last quarter.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.